PTEN is Destabilized by Phosphorylation on Thr366

Overview

Journal Biochem J

Specialty Biochemistry

Date 2007 Apr 21

PMID 17444818

Citations 75

Authors

Helene Maccario

Nevin M Perera

Lindsay Davidson

C Peter Downes

Nick R Leslie

Affiliations

Soon will be listed here.

Abstract

Although PTEN (phosphatase and tensin homologue deleted on chromosome 10) is one of the most commonly mutated tumour suppressors in human cancers, loss of PTEN expression in the absence of mutation appears to occur in an even greater number of tumours. PTEN is phosphorylated in vitro on Thr366 and Ser370 by GSK3 (glycogen synthase kinase 3) and CK2 (casein kinase 2) respectively, and specific inhibitors of these kinases block these phosphorylation events in cultured cells. Although mutation of these phosphorylation sites did not alter the phosphatase activity of PTEN in vitro or in cells, blocking phosphorylation of Thr366 by either mutation or GSK3 inhibition in glioblastoma cell lines led to a stabilization of the PTEN protein. Our data support a model in which the phosphorylation of Thr366 plays a role in destabilizing the PTEN protein.

Citing Articles

Circadian Control of Protein Synthesis.

James N, ONeill J Bioessays. 2024; 47(3):e202300158.

PMID: 39668398 PMC: 11848126. DOI: 10.1002/bies.202300158.

Distinct early role of PTEN regulation during HCMV infection of monocytes.

Chesnokova L, Mosher B, Fulkerson H, Nam H, Shakya A, Yurochko A Proc Natl Acad Sci U S A. 2024; 121(12):e2312290121.

PMID: 38483999 PMC: 10962971. DOI: 10.1073/pnas.2312290121.

Regulatory mechanisms triggered by enzyme interactions with lipid membrane surfaces.

Yu J, Boehr D Front Mol Biosci. 2023; 10:1306483.

PMID: 38099197 PMC: 10720463. DOI: 10.3389/fmolb.2023.1306483.

PINK1-PTEN axis promotes metastasis and chemoresistance in ovarian cancer via non-canonical pathway.

Zheng F, Zhong J, Chen K, Shi Y, Wang F, Wang S J Exp Clin Cancer Res. 2023; 42(1):295.

PMID: 37940999 PMC: 10633943. DOI: 10.1186/s13046-023-02823-w.

Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia.

Bruserud O, Reikvam H Cancers (Basel). 2023; 15(14).

PMID: 37509370 PMC: 10378128. DOI: 10.3390/cancers15143711.

References

Maehama T, Taylor G, Dixon J . PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem. 2001; 70:247-79. DOI: 10.1146/annurev.biochem.70.1.247. View

Vazquez F, Grossman S, Takahashi Y, Rokas M, Nakamura N, Sellers W . Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem. 2001; 276(52):48627-30. DOI: 10.1074/jbc.C100556200. View

Zhou X, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomaki P, de la Chapelle A . PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol. 2002; 161(2):439-47. PMC: 1850747. DOI: 10.1016/S0002-9440(10)64200-9. View

Miller S, Lou D, Seldin D, Lane W, Neel B . Direct identification of PTEN phosphorylation sites. FEBS Lett. 2002; 528(1-3):145-53. DOI: 10.1016/s0014-5793(02)03274-x. View

Das S, Dixon J, Cho W . Membrane-binding and activation mechanism of PTEN. Proc Natl Acad Sci U S A. 2003; 100(13):7491-6. PMC: 164614. DOI: 10.1073/pnas.0932835100. View

Wu W, Wang X, Zhang W, Reed W, Samet J, Whang Y . Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells. J Biol Chem. 2003; 278(30):28258-63. DOI: 10.1074/jbc.M303318200. View

Hong K, Kim K, Shin H, Lee J, Choi J, Kwak Y . Cilostazol prevents tumor necrosis factor-alpha-induced cell death by suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and activation of Akt/cyclic AMP response element-binding protein phosphorylation. J Pharmacol Exp Ther. 2003; 306(3):1182-90. DOI: 10.1124/jpet.103.052365. View

Sulis M, Parsons R . PTEN: from pathology to biology. Trends Cell Biol. 2003; 13(9):478-83. DOI: 10.1016/s0962-8924(03)00175-2. View

Trotman L, Niki M, Dotan Z, Koutcher J, Di Cristofano A, Xiao A . Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003; 1(3):E59. PMC: 270016. DOI: 10.1371/journal.pbio.0000059. View

10.

Parsons R . Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol. 2004; 15(2):171-6. DOI: 10.1016/j.semcdb.2003.12.021. View

11.

Sansal I, Sellers W . The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004; 22(14):2954-63. DOI: 10.1200/JCO.2004.02.141. View

12.

Leslie N, Downes C . PTEN function: how normal cells control it and tumour cells lose it. Biochem J. 2004; 382(Pt 1):1-11. PMC: 1133909. DOI: 10.1042/BJ20040825. View

13.

Khan S, Kumagai T, Vora J, Bose N, Sehgal I, Koeffler P . PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer. 2004; 112(3):407-10. DOI: 10.1002/ijc.20447. View

14.

Okahara F, Ikawa H, Kanaho Y, Maehama T . Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J Biol Chem. 2004; 279(44):45300-3. DOI: 10.1074/jbc.C400377200. View

15.

Alessi D, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P . Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996; 15(23):6541-51. PMC: 452479. View

16.

Steck P, Pershouse M, Jasser S, Yung W, Lin H, Ligon A . Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997; 15(4):356-62. DOI: 10.1038/ng0497-356. View

17.

Whang Y, Wu X, Suzuki H, Reiter R, Tran C, Vessella R . Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A. 1998; 95(9):5246-50. PMC: 20246. DOI: 10.1073/pnas.95.9.5246. View

18.

Di Cristofano A, Kotsi P, Peng Y, Cordon-Cardo C, Elkon K, Pandolfi P . Impaired Fas response and autoimmunity in Pten+/- mice. Science. 1999; 285(5436):2122-5. DOI: 10.1126/science.285.5436.2122. View

19.

Salvesen H, Stefansson I, Kretzschmar E, Gruber P, MacDonald N, Ryan A . Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol. 2004; 25(6):1615-23. View

20.

Pagano M, Andrzejewska M, Ruzzene M, Sarno S, Cesaro L, Bain J . Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004; 47(25):6239-47. DOI: 10.1021/jm049854a. View